Skip to content

To evaluate the efficacy of eranda kshar yog and phaltrikadi yog in the management of medoroga w.r.t dyslipidemia

A RANDOMISED COMPARATIVE CLINICAL STUDY TO EVALUATE THE EFFICACY OF â??PHALTRIKADI YOGAâ??AND â??ERANDA KSHAR YOGAâ?? IN THE MANAGEMENT OF MEDOROGA W.S.R. TO DYSLIPIDEMIA

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/05/052340
Enrollment
60
Registered
2023-05-08
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E785- Hyperlipidemia, unspecified

Interventions

None listed

Sponsors

Ayurvedic and Unani Tibia College Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a) Patients between the age group of 18-60 years of either sex. b) Willing and able to participate in the study for 90 days. c) Patients having Serum Cholesterol 201-400mg/dl, Serum Triglycerides 151- 400 mg/dI LDL Cholesterol 131-250 mg/dl, HDL Details Cholesterol d)Patients with strictly controlled Diabetes Mellitus (HbA1c less than or equal to 7%)

Exclusion criteria

Exclusion criteria: 1) Patients who have a past history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, congestive heart failure ,Stroke or severe Arrhythmia, Unstable angina in the last six months. 2) Patients on prolonged ( >6weeks) medication with corticosteroids, antidepressants, anti cholinergics, immunosuppressant 3) Patients with poorly controlled hypertension (systolic >140 and diastolic >90 mm of Hg) despite of antihypertensive agents. 4)Patients with uncontrolled diabetes mellitus and HbA1C >7% 5) Patients with evidence of malignancy. 6)Hypersensitivity to any of the trial drugs or their ingredients. 7)Patients who have completed participation in any other clinical trial drugs or their ingredients in one month 8)Patients who have received any cholesterol lowering medication (allopathic drug) within last two weeks. 9)Pregnancy and Lactating mother. .

Design outcomes

Primary

MeasureTime frame
Lipid Profile-total cholesterol, LDL-C, HDL-C, Triglycerides Timepoint: 3 months

Secondary

MeasureTime frame
A detailed evaluation of biochemical investigations(Hemogram ,RBS,Urine- routine and microscopic examination.,Kidney Function tests,Liver function tests will be repeated at the end of the study.) Timepoint: 3 months

Countries

India

Contacts

Public ContactDr Sujata Yadav

A and U Tibbia College & Hospital

sujatakcdelhi@gmail.com9354925030

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026